Full Text Journal Articles by
Author Shakti H Ramkissoon

Advertisement

Find full text journal articles






JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.

Megan J Fitzpatrick, Lucas R Massoth, Chelsea Marcus, Jo-Anne Vergilio, Eric Severson, Daniel Duncan, Shakti H Ramkissoon, Robert P Hasserjian, Annette S Kim, Aliyah R Sohani, Erik A Williams, Valentina Nardi,

Peripheral T-cell lymphoma (PTCL) comprises a heterogenous group of rare mature T-cell neoplasms. While some PTCL subtypes are well-characterized by histology, immunophenotype, and recurrent molecular alterations, others remain incompletely defined. In particular, the distinction between CD30+ PTCL, not otherwise specified and anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma can ... Read more >>

Am J Surg Pathol (The American journal of surgical pathology)
[2021, 45(7):895-904]

Cited: 0 times

View full text PDF listing >>



Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.

Richard S P Huang, James Haberberger, Kimberly McGregor, Douglas A Mata, Brennan Decker, Matthew C Hiemenz, Mirna Lechpammer, Natalie Danziger, Kelsie Schiavone, James Creeden, Ryon P Graf, Roy Strowd, Glenn J Lesser, Evangelia D Razis, Rupert Bartsch, Athina Giannoudis, Talvinder Bhogal, Nancy U Lin, Lajos Pusztai, Jeffrey S Ross, Carlo Palmieri, Shakti H Ramkissoon,

<h4>Background</h4>Among breast carcinoma patients with metastatic disease, 15-30% will eventually develop brain metastases. We examined the genomic landscape of a large cohort of breast carcinoma brain metastases (BCBMs) and compared them to a cohort of primary breast carcinomas (BCs).<h4>Material and methods</h4>We retrospectively analyzed 733 BCBMs tested with comprehensive genomic profiling ... Read more >>

Oncologist (The oncologist)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.

Lucas R Massoth, Yin P Hung, Judith A Ferry, Robert P Hasserjian, Valentina Nardi, G Petur Nielsen, Sam Sadigh, Vinayak Venkataraman, Martin Selig, Alison M Friedmann, Wesley Samore, Jonathan Keith Killian, Riza Milante, Joseph Giessinger, Kathleen Foley-Peres, Chelsea Marcus, Eric Severson, Daniel Duncan, Smruthy Sivakumar, Jeffrey S Ross, Vikram Desphande, Shakti H Ramkissoon, Jo-Anne Vergilio, Abner Louissaint, Lawrence R Zukerberg, Erik A Williams,

<h4>Background</h4>Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histiocytosis and Erdheim-Chester disease have been well described, other less common and often aggressive tumors in this broad category remain poorly characterized, and comparison studies ... Read more >>

Oncologist (The oncologist)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.

Richard S P Huang, James Haberberger, Lukas Harries, Eric Severson, Daniel L Duncan, N Lynn Ferguson, Amanda Hemmerich, Claire Edgerly, Karthikeyan Murugesan, Jinpeng Xiao, Deborah McEwan, Oliver Holmes, Matthew Hiemenz, Jeffrey Venstrom, Julia A Elvin, James Creeden, Douglas I Lin, Jeffrey S Ross, Shakti H Ramkissoon,

<h4>Introduction</h4>Pembrolizumab was approved with an accompanying companion diagnostic (CDx) assay (PD-L1 DAKO 22C3) for urothelial carcinoma (UC). In this study, we further characterize the clinicopathologic and genomic features of UC that are programmed death-ligand 1 (PD-L1) positive.<h4>Materials and methods</h4>The cohort of this study consisted of a total of 528 consecutive ... Read more >>

Oncologist (The oncologist)
[2021, 26(5):375-382]

Cited: 0 times

View full text PDF listing >>



Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.

Richard S P Huang, James Haberberger, Karthikeyan Murugesan, Natalie Danziger, Matthew Hiemenz, Eric Severson, Daniel L Duncan, Shakti H Ramkissoon, Jeffrey S Ross, Julia A Elvin, Douglas I Lin,

Positive program death-ligand 1 (PD-L1) immunohistochemistry (IHC) is an approved companion diagnostic guiding the use of immune checkpoint inhibitors in uterine cervical carcinoma (CXC). The clinical and genomic features of PD-L1-positive (PD-L1<sup>positive</sup>) CXC have not been previously described. We reviewed the clinicopathologic and molecular features of 647 CXC cases that ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2021, :]

Cited: 0 times

View full text PDF listing >>



LGG-01. CLINICAL MANAGEMENT AND GENOMIC PROFILING OF PEDIATRIC LOW-GRADE GLIOMAS IN SAUDI ARABIA

Nahla A Mobark, Musa Alharbi, Ali Abdullah O Balbaid, Lamees Al-Habeeb, Latifa AlMubarak, Rasha Alaljelaify, Mariam AlSaeed, Amal Almutairi, Fatmah A Alanazi, Yara Bashawri, Maqsood Ahmad, Ayman Al-Banyan, Fahad E Alotabi, Duna Barakeh, Malak AlZahrani, Hisham Al-Khalidi, Abdulrazag Ajlan, Lori A Ramkissoon, Shakti H Ramkissoon, Malak Abedalthagafi,

Abstract Pediatric Low Grade Gliomas (PLGGs) display heterogeneity regarding morphology, genomic drivers and clinical outcomes. The treatment modality dictates the outcome and optimizing patient management can be challenging. In this study, we profiled a targeted panel of cancer-related genes in 37 Saudi Arabian patients with pLGGs to identify genetic abnormalities ... Read more >>

Neuro Oncol (Neuro-oncology)
[2020, 22(Suppl 3):iii366-iii366]

Cited: 0 times

View full text PDF listing >>



FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas.

Radwa Sharaf, Dean C Pavlick, Garrett M Frampton, Maureen Cooper, Jacqueline Jenkins, Natalie Danziger, James Haberberger, Brian M Alexander, Timothy Cloughesy, William H Yong, Linda M Liau, Phioanh L Nghiemphu, Matthew Ji, Albert Lai, Shakti H Ramkissoon, Lee A Albacker,

<h4>Background</h4>Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform.<h4>Methods</h4>Testing was performed on glioma samples as part of clinical ... Read more >>

Neurooncol Adv (Neuro-oncology advances)
[2021, 3(1):vdab017]

Cited: 0 times

View full text PDF listing >>



Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.

Abirami Sivapiragasam, Prashanth Ashok Kumar, Ethan S Sokol, Lee A Albacker, Jonathan K Killian, Shakti H Ramkissoon, Richard S P Huang, Eric A Severson, Charlotte A Brown, Natalie Danziger, Kimberly McGregor, Jeffrey S Ross,

We examined a large dataset of female metastatic breast cancers (MBCs) profiled with comprehensive genomic profiling (CGP) to identify the prevalence and distribution of immunotherapy responsiveness-associated biomarkers. DNA was extracted from 3831 consecutive MBCs: 1237 (ER<sup>pos</sup> /HER2<sup>neg</sup> ), 1953 ER<sup>neg</sup> /HER2<sup>amp</sup> , and 641 triple-negative breast cancer (TNBC). CGP was ... Read more >>

Cancer Med (Cancer medicine)
[2021, 10(1):53-61]

Cited: 2 times

View full text PDF listing >>



Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors.

Lori A Ramkissoon, Worthy Pegram, James Haberberger, Natalie Danziger, Glenn Lesser, Roy Strowd, Sonika Dahiya, Thomas J Cummings, Wenya Linda Bi, Malak Abedalthagafi, Pratheesh Sathyan, Kimberly McGregor, Prasanth Reddy, Eric Severson, Erik Williams, Douglas Lin, Claire Edgerly, Richard S P Huang, Amanda Hemmerich, James Creeden, Charlotte Brown, Jeffrey Venstrom, Priti Hegde, Jeffrey S Ross, Brian M Alexander, Julia Elvin, Shakti H Ramkissoon,

Despite advances in systemic therapies for solid tumors, the development of brain metastases remains a significant contributor to overall cancer mortality and requires improved methods for diagnosing and treating these lesions. Similarly, the prognosis for malignant primary brain tumors remains poor with little improvement in overall survival over the last ... Read more >>

Front Neurol (Frontiers in neurology)
[2020, 11:544680]

Cited: 0 times

View full text PDF listing >>



Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin.

Douglas I Lin, Nikunj Shah, Julie Y Tse, Jonathan K Killian, Amanda Hemmerich, Claire Edgerly, James Haberberger, Eric A Severson, Richard S P Huang, Shakti H Ramkissoon, Jo-Anne Vergilio, Jeffrey S Ross, Julia A Elvin,

Mesonephric carcinoma is a rare cancer that most often arises within the cervix, and less frequently, in the ovary and endometrium. A retrospective search of our CLIA-certified and CAP-accredited reference molecular laboratory database (Foundation Medicine, Inc.) identified 20 mesonephric or mesonephric-like, cervical (n = 10), endometrial (n = 5), ovarian (n = 4) or peri-bladder (n = 1) ... Read more >>

Gynecol Oncol Rep (Gynecologic oncology reports)
[2020, 34:100652]

Cited: 1 time

View full text PDF listing >>



Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.

Jaclyn J Renfrow, Michael H Soike, James L West, Shakti H Ramkissoon, Linda Metheny-Barlow, Ryan T Mott, Carol A Kittel, Ralph B D'Agostino, Stephen B Tatter, Adrian W Laxton, Mark B Frenkel, Gregory A Hawkins, Denise Herpai, Stephanie Sanders, Jann N Sarkaria, Glenn J Lesser, Waldemar Debinski, Roy E Strowd,

Hypoxia inducible factor (HIFs) signaling contributes to malignant cell behavior in glioblastoma (GBM). We investigated a novel HIF2α inhibitor, PT2385, both in vitro, with low-passage patient-derived cell lines, and in vivo, using orthotopic models of glioblastoma. We focused on analysis of HIF2α expression in situ, cell survival/proliferation, and survival in ... Read more >>

Sci Rep (Scientific reports)
[2020, 10(1):15195]

Cited: 1 time

View full text PDF listing >>



Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.

Douglas I Lin, Jonathan K Killian, Jeffrey M Venstrom, Shakti H Ramkissoon, Jeffrey S Ross, Julia A Elvin,

Malignant Brenner tumor is a rare primary ovarian carcinoma subtype that may present diagnostic and therapeutic conundrums. Here, we characterize the genomics of 11 malignant Brenner tumors, which represented 0.1% of 14,153 clinically advanced ovarian carcinomas submitted for genomic profiling during the course of clinical care. At the time of ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2021, 34(5):983-993]

Cited: 0 times

View full text PDF listing >>



Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.

Richard S P Huang, Xinyan Li, James Haberberger, Ethan Sokol, Eric Severson, Daniel L Duncan, Amanda Hemmerich, Claire Edgerly, Erik Williams, Julia Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas Lin, Matthew Hiemenz, Jinpeng Xiao, Deborah McEwan, Oliver Holmes, Natalie Danziger, Rachel Erlich, Garrett Frampton, Michael B Cohen, Kimberly McGregor, Prasanth Reddy, Dawn Cardeiro, Rachel Anhorn, Jeffrey Venstrom, Brian Alexander, Charlotte Brown, Lajos Pusztai, Jeffrey S Ross, Shakti H Ramkissoon,

<h4>Background</h4>We examined the current biomarker landscape in breast cancer when programmed death-ligand 1 (PD-L1) testing is integrated with comprehensive genomic profiling (CGP).<h4>Material and methods</h4>We analyzed data from samples of 312 consecutive patients with breast carcinoma tested with both CGP and PD-L1 (SP142) immunohistochemistry (IHC) during routine clinical care. These samples ... Read more >>

Oncologist (The oncologist)
[2020, 25(11):943-953]

Cited: 2 times

View full text PDF listing >>



Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.

Erik A Williams, Sandro Santagata, Hiroaki Wakimoto, Ganesh M Shankar, Fred G Barker, Radwa Sharaf, Abhinav Reddy, Phoebe Spear, Brian M Alexander, Jeffrey S Ross, Priscilla K Brastianos, Daniel P Cahill, Shakti H Ramkissoon, Tareq A Juratli,

<h4>Background</h4>Genomic studies of high-grade/progressive meningiomas have reported a heterogeneous mutation spectrum, identifying few recurrently mutated genes. Most studies have been underpowered to detect genomic subclasses of aggressive meningiomas due to relatively small number of available samples. Here, we present a genomic survey of one of the largest multi-institutional cohorts of ... Read more >>

Acta Neuropathol Commun (Acta neuropathologica communications)
[2020, 8(1):171]

Cited: 2 times

View full text PDF listing >>



A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.

Richard S P Huang, James Haberberger, Eric Severson, Daniel L Duncan, Amanda Hemmerich, Claire Edgerly, Naomi Lynn Ferguson, Erik Williams, Julia Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas I Lin, Julie Tse, Matthew Hiemenz, Clarence Owens, Natalie Danziger, Priti S Hegde, Jeffrey Venstrom, Brian Alexander, Jeffrey S Ross, Shakti H Ramkissoon,

PD-L1 immunohistochemistry (IHC) currently has the most Food and Drug Administration (FDA) approvals as a companion diagnostic (CDx) for immunotherapies in specific tumor types; however, multiple other immunotherapy biomarkers exist. We performed this study to examine and report the prevalence of PD-L1 expression in a wide variety of tumor types ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2021, 34(2):252-263]

Cited: 4 times

View full text PDF listing >>



CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion.

Erik A Williams, Radwa Sharaf, Brennan Decker, Adrienne J Werth, Helen Toma, Meagan Montesion, Ethan S Sokol, Dean C Pavlick, Nikunj Shah, Kevin Jon Williams, Jeffrey M Venstrom, Brian M Alexander, Jeffrey S Ross, Lee A Albacker, Douglas I Lin, Shakti H Ramkissoon, Julia A Elvin,

<h4>Purpose</h4>Leiomyosarcoma (LMS) harbors frequent mutations in <i>TP53</i> and <i>RB1</i> but few actionable genomic alterations. Here, we searched for recurrent actionable genomic alterations in LMS that occur in the absence of common untreatable oncogenic drivers.<h4>Methods</h4>Tissues from 276,645 unique advanced cancers, including 2,570 uterine and soft tissue LMS, were sequenced by hybrid-capture-based ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2020, 4:]

Cited: 0 times

View full text PDF listing >>



CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features.

Erik A Williams, Meagan Montesion, Brian M Alexander, Shakti H Ramkissoon, Julia A Elvin, Jeffrey S Ross, Kevin Jon Williams, Krzysztof Glomski, Jacob R Bledsoe, Julie Y Tse, Mark C Mochel,

Mutations in the tumor suppressor CYLD, known to be causative of cylindromas, were recently described in a subset of high-risk (hr) HPV-positive head and neck squamous cell carcinomas (HNSCC). Pathologic and genetic characterization of these CYLD-mutant carcinomas, however, remains limited. Here, we investigated whether CYLD mutations characterize a histopathologically and ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2021, 34(2):358-370]

Cited: 0 times

View full text PDF listing >>



Molecular and clinicopathologic features of gliomas harboring NTRK fusions.

Matthew Torre, Varshini Vasudevaraja, Jonathan Serrano, Michael DeLorenzo, Seth Malinowski, Anne-Florence Blandin, Melanie Pages, Azra H Ligon, Fei Dong, David M Meredith, MacLean P Nasrallah, Craig Horbinski, Sonika Dahiya, Keith L Ligon, Mariarita Santi, Shakti H Ramkissoon, Mariella G Filbin, Matija Snuderl, Sanda Alexandrescu,

Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes are detected in ≤2% of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK inhibitors, which are among the first Food and Drug Administration-approved targeted therapies for NTRK-fused gliomas, has generated significant clinical interest in characterizing these tumors. In this ... Read more >>

Acta Neuropathol Commun (Acta neuropathologica communications)
[2020, 8(1):107]

Cited: 6 times

View full text PDF listing >>



Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib.

Musa Alharbi, Nahla Ali Mobark, Ali Abdullah O Balbaid, Fatmah A Alanazi, Wael Abdel Rahman Aljabarat, Eman A Bakhsh, Shakti H Ramkissoon, Malak Abedalthagafi,

JCO Precis Oncol (JCO precision oncology)
[2020, 4:]

Cited: 2 times

View full text PDF listing >>



Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.

Roshal R Patel, Shakti H Ramkissoon, Jeffrey Ross, Lauren Weintraub,

BACKGROUND:Tumor mutational burden (TMB) and driver mutations are potential biomarkers to guide targeted therapy selection. Malignant gliomas with high TMB in children may preferentially benefit from treatment with immune checkpoint inhibitors (ICPIs). Higher TMB may relate to lower incidence of driver mutations, but this relationship has not been studied in ... Read more >>

Pediatr Blood Cancer (Pediatric blood & cancer)
[2020, 67(7):e28338]

Cited: 4 times

View full text PDF listing >>



Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.

Erik A Williams, Adrienne J Werth, Radwa Sharaf, Meagan Montesion, Ethan S Sokol, Dean C Pavlick, Molly McLaughlin-Drubin, Rachel Erlich, Helen Toma, Kevin Jon Williams, Jeff M Venstrom, Brian M Alexander, Nikunj Shah, Natalie Danziger, Amanda C Hemmerich, Eric A Severson, Jonathan Keith Killian, Douglas I Lin, Jeffrey S Ross, Julie Y Tse, Shakti H Ramkissoon, Mark C Mochel, Julia A Elvin,

<h4>Purpose</h4>Vulvar squamous cell carcinoma (vSCC) encompasses two predominant variants: one associated with detectable high-risk strains of human papillomavirus (hrHPV) and a second form often occurring in the context of chronic dermatitis in postmenopausal women. Genomic assessment of a large-scale cohort of patients with aggressive vSCC may identify distinct mutational signatures.<h4>Materials ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2020, 4:]

Cited: 2 times

View full text PDF listing >>



Mechanisms and therapeutic implications of hypermutation in gliomas.

Mehdi Touat, Yvonne Y Li, Adam N Boynton, Liam F Spurr, J Bryan Iorgulescu, Craig L Bohrson, Isidro Cortes-Ciriano, Cristina Birzu, Jack E Geduldig, Kristine Pelton, Mary Jane Lim-Fat, Sangita Pal, Ruben Ferrer-Luna, Shakti H Ramkissoon, Frank Dubois, Charlotte Bellamy, Naomi Currimjee, Juliana Bonardi, Kenin Qian, Patricia Ho, Seth Malinowski, Leon Taquet, Robert E Jones, Aniket Shetty, Kin-Hoe Chow, Radwa Sharaf, Dean Pavlick, Lee A Albacker, Nadia Younan, Capucine Baldini, Maïté Verreault, Marine Giry, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agusti Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle-Donadey, Dimitri Psimaras, Eudocia Q Lee, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S Barnholtz-Sloan, Arnab Chakravarti, Wenya Linda Bi, E Antonio Chiocca, Katie Pricola Fehnel, Sanda Alexandrescu, Susan N Chi, Daphne Haas-Kogan, Tracy T Batchelor, Garrett M Frampton, Brian M Alexander, Raymond Y Huang, Azra H Ligon, Florence Coulet, Jean-Yves Delattre, Khê Hoang-Xuan, David M Meredith, Sandro Santagata, Alex Duval, Marc Sanson, Andrew D Cherniack, Patrick Y Wen, David A Reardon, Aurélien Marabelle, Peter J Park, Ahmed Idbaih, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L Ligon,

A high tumour mutational burden (hypermutation) is observed in some gliomas<sup>1-5</sup>; however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here we comprehensively analyse the molecular determinants of mutational burden and signatures in 10,294 gliomas. We delineate two main pathways to ... Read more >>

Nature (Nature)
[2020, 580(7804):517-523]

Cited: 45 times

View full text PDF listing >>



CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma.

Erik A Williams, Meagan Montesion, Radwa Sharaf, James Corines, Parth J Patel, Brendan J Gillespie, Dean C Pavlick, Ethan S Sokol, Brian M Alexander, Kevin Jon Williams, Julia A Elvin, Jeffrey S Ross, Shakti H Ramkissoon, Amanda C Hemmerich, Julie Y Tse, Mark C Mochel,

Rare reports of anal carcinoma (AC) describe histologic resemblance to cutaneous cylindroma, but mutations in the tumor suppressor CYLD, the gene responsible for familial and sporadic cylindromas, have not been systematically investigated in AC. Here, we investigate CYLD-mutant AC, focusing on molecular correlates of distinct histopathology. Comprehensive genomic profiling (hybrid-capture-based ... Read more >>

Mod Pathol (Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc)
[2020, 33(12):2614-2625]

Cited: 3 times

View full text PDF listing >>



Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features.

Erik A Williams, Hiroaki Wakimoto, Ganesh M Shankar, Fred G Barker, Priscilla K Brastianos, Sandro Santagata, Ethan S Sokol, Dean C Pavlick, Nikunj Shah, Abhinav Reddy, Jeffrey M Venstrom, Brian M Alexander, Jeffrey S Ross, Daniel P Cahill, Shakti H Ramkissoon, Tareq A Juratli,

Acta Neuropathol (Acta neuropathologica)
[2020, 140(1):89-93]

Cited: 2 times

View full text PDF listing >>



Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.

Nahla A Mobark, Musa Alharbi, Lamees Alhabeeb, Latifa AlMubarak, Rasha Alaljelaify, Mariam AlSaeed, Amal Almutairi, Fatmah Alqubaishi, Maqsood Ahmad, Ayman Al-Banyan, Fahad E Alotabi, Duna Barakeh, Malak AlZahrani, Hisham Al-Khalidi, Abdulrazag Ajlan, Lori A Ramkissoon, Shakti H Ramkissoon, Malak Abedalthagafi,

Pediatric Low Grade Gliomas (PLGGs) display heterogeneity regarding morphology, genomic drivers and clinical outcomes. The treatment modality dictates the outcome and optimizing patient management can be challenging. In this study, we profiled a targeted panel of cancer-related genes in 37 Saudi Arabian patients with pLGGs to identify genetic abnormalities that ... Read more >>

PLoS One (PloS one)
[2020, 15(1):e0228356]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.0507 s